<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728581</url>
  </required_header>
  <id_info>
    <org_study_id>W021-001</org_study_id>
    <nct_id>NCT04728581</nct_id>
  </id_info>
  <brief_title>Improving Sleep After TKA Using Mirtazapine and Quetiapine</brief_title>
  <official_title>Mirtazapine and Quetiapine as Treatment for Postoperative Sleep Disturbance After Fast-track Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Anna Ziekenhuis, Geldrop, Netherlands</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Anna Ziekenhuis, Geldrop, Netherlands</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of mirtazapine and quetiapine for improvement of sleep quality after TKA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background After knee replacement surgery there is a loss of quantity and quality of sleep.&#xD;
      Loss of sleep is associated with increased pain perception. Subsequently, patients use more&#xD;
      analgesic medication and it takes them longer to fully recover from surgery. Low doses of the&#xD;
      tetracyclic antidepressant mirtazapine and the neuroleptic quetiapine are nowadays off-label&#xD;
      prescribed for insomnia and improve length and quality of deep sleep phases. Quetiapine and&#xD;
      mirtazapine could improve sleep after knee replacement surgery and improve patient recovery.&#xD;
      This placebo-controlled, randomized, double-blind study investigates the effect of quetiapine&#xD;
      and mirtazapine on functional recovery after total knee arthroplasty.&#xD;
&#xD;
      Methods This is a prospective, single center, double-blinded randomized controlled trial. 165&#xD;
      patients with knee osteoarthritis scheduled for total knee arthroplasty will be randomly&#xD;
      allocated to a low-dose quetiapine (LDQ), a low-dose mirtazapine (LDM) group or a placebo&#xD;
      group. Outcomes will be evaluated at baseline, 2, 4, 6 and 12 weeks after surgery. Functional&#xD;
      outcome after total knee arthroplasty is measured using a patient related outcome measure&#xD;
      through the Oxford Knee Score (OKS). In order to measure postoperative sleep quality,&#xD;
      patients will be monitored using the Leeds Sleep evaluation questionnaire (LSEQ).&#xD;
      Furthermore, pain is registered using a visual analogue scale (VAS), weekly opioid use is&#xD;
      monitored, and general health status is reported through the EQ-5D. Analyses will be&#xD;
      conducted on an intention-to-treat basis using logistic and linear mixed regression models.&#xD;
      This trial complies with the SPIRIT guidelines for randomized controlled trials.&#xD;
&#xD;
      Discussion This study will provide clinicians with evidence whether quetiapine contributes to&#xD;
      rehabilitation of patients undergoing fast-track knee replacement surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Oxford Knee Score (OKS)</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>Validated functional knee score after TKA, minimum score 12 (best outcome), maximum score 60 (worst outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leeds Sleep Evaluation questionnaire (LSEQ)</measure>
    <time_frame>1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery</time_frame>
    <description>Validated sleep score in 3 dimensions of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) for fatigue</measure>
    <time_frame>1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery</time_frame>
    <description>Visual analogue reporting of fatigue after sleep, indicated on a 0 (best outcome) to 100 (worst outcome) mm line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) for sleep quality</measure>
    <time_frame>1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery</time_frame>
    <description>Visual analogue reporting of quality sleep, indicated on a 0 (worst outcome) to 100 (best outcome) mm line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) for pain in rest</measure>
    <time_frame>1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery</time_frame>
    <description>Visual analogue reporting of knee pain while resting, indicated on a 0 (best outcome) to 100 (worst outcome) mm line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) for pain during activity</measure>
    <time_frame>1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery</time_frame>
    <description>Visual analogue reporting of knee pain during exercises, indicated on a 0 (best outcome) to 100 (worst outcome) mm line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol (EQ) 5D</measure>
    <time_frame>1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery</time_frame>
    <description>General well being score, full health represented by 11111 score (overall score for the Netherlands of 1,000), worst health represented by 55555 score (overal score for the Netherlands of -0,329)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine use</measure>
    <time_frame>1 week before surgery; first day postoperative; 2; 4; 6; 12 weeks after surgery</time_frame>
    <description>Total amount (mg) morphine use after surgery is documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford knee score</measure>
    <time_frame>1 week before surgery; first day postoperative; 2; 4; 12 weeks after surgery</time_frame>
    <description>Validated functional knee score after TKA, minimum score 12 (best outcome), maximum score 60 (worst outcome)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>use of placebo during first 2 weeks after TKA surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Mirtazapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Mirtazapine 3.75mg before lights-out, allowed to increase medication to 7.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Quetiapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use of Quetiapine 3.125mg before lights-out, allowed to increase medication to 6.25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.</description>
    <arm_group_label>Low dose Mirtazapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.</description>
    <arm_group_label>Low dose Quetiapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a gelatinous capsule without an active ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indication for TKA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  use of benzodiazepines&#xD;
&#xD;
          -  use of anti-depressants&#xD;
&#xD;
          -  use of oxycodone&#xD;
&#xD;
          -  patients diagnosed with obstructive sleep apnea syndrome, severe respiratory&#xD;
             insufficiency, or myasthenia&#xD;
&#xD;
          -  a known hypersensitivity to mirtazapine, quetiapine and/or related to the gelatinous&#xD;
             (placebo) capsule&#xD;
&#xD;
          -  insufficient understanding of the Dutch language.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Walter van der Weegen</last_name>
    <phone>06-34282788</phone>
    <email>w.vanderweegen@st-anna.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michiel Siebelt</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Knowledge Center for Orthopedic Surgery, St. Anna hospital</name>
      <address>
        <city>Geldrop</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna hospital</name>
      <address>
        <city>Geldrop</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Walter van der Weegen</last_name>
      <phone>06-34282788</phone>
      <email>w.vander.weegen@st-anna.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 23, 2021</last_update_submitted>
  <last_update_submitted_qc>January 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Anna Ziekenhuis, Geldrop, Netherlands</investigator_affiliation>
    <investigator_full_name>Walter van der Weegen</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data free accessible upon request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>First year after publication</ipd_time_frame>
    <ipd_access_criteria>After written request, and received permission</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

